What does Panacea Pharma do?

Panacea Pharma is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 10 December 2012, 1 establishment.

What is the address of Panacea Pharma?

The registered office of Panacea Pharma is located at Lierbaan 37, 2580 Putte.

Is Panacea Pharma still active?

Yes. According to the CBE (30 October 2026) Panacea Pharma is active, legal situation “Normale toestand”, started on 10 December 2012.

Is Panacea Pharma registered on Peppol?

Yes, Panacea Pharma is registered on the Peppol network with ID 0208:0501960053.

What is the enterprise number of Panacea Pharma?

The enterprise number of Panacea Pharma is BE0501960053.

When was Panacea Pharma founded?

Panacea Pharma was founded on 10 December 2012.

Who are the directors of Panacea Pharma?

According to the 2025 annual accounts, the directors of Panacea Pharma are: Stefan Puttemans.

Is Panacea Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 December 2012; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Panacea Pharma make in 2025?

Panacea Pharma posted a profit after taxes of € 63,348 in financial year 2025.

What is the revenue of Panacea Pharma?

As a small company, Panacea Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 111,948.

Panacea Pharma (Private Limited) - Putte - BE0501960053

Dossier Panacea Pharma, printed on 30 October 2026 from databakkes.be/en/0501960053/panacea-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 57 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Panacea Pharma from Putte, company number BE0501960053, closed financial year 2025 with a result of € 63,348 after tax. For that financial year Panacea Pharma recorded a gross margin of € 111,948 and equity of € 1 million. Compared with financial year 2024, the result moved from € 114,285 to € 63,348. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 28, 2025.

What it is worth Growing

€ 1 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 63,348

▼ 45% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 29,044

▼ 21% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 958,837.

Debts at end 2025

Bank debt ≈ 16 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 539,981

▼ 6% vs 2024

€ 34,546 is repaid this year. At this pace the long-term loan is gone in ≈ 16 years.

Owed to suppliers

€ 478

▼ 63% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 15,069

▼ 35% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 68,402 Gross margin 2022: € 68,402 First fiscal year in the series	€ 70,084 Gross margin 2023: € 70,084 ▲ 2% vs 2022 (€ 68,402) Favourable step	€ 66,727 Gross margin 2024: € 66,727 ▼ 5% vs 2023 (€ 70,084) Unfavourable step	€ 111,948 Gross margin 2025: € 111,948 ▲ 68% vs 2024 (€ 66,727) Favourable step	▲ 68%
Profit after taxes	€ 189,414 Profit after taxes 2022: € 189,414 First fiscal year in the series	€ 115,335 Profit after taxes 2023: € 115,335 ▼ 39% vs 2022 (€ 189,414) Unfavourable step	€ 114,285 Profit after taxes 2024: € 114,285 ▼ 1% vs 2023 (€ 115,335) Unfavourable step	€ 63,348 Profit after taxes 2025: € 63,348 ▼ 45% vs 2024 (€ 114,285) Unfavourable step	▼ 45%
Equity	€ 770,469 Equity 2022: € 770,469 First fiscal year in the series	€ 877,204 Equity 2023: € 877,204 ▲ 14% vs 2022 (€ 770,469) Favourable step	€ 945,489 Equity 2024: € 945,489 ▲ 8% vs 2023 (€ 877,204) Favourable step	€ 1,008,837 Equity 2025: € 1,008,837 ▲ 7% vs 2024 (€ 945,489) Favourable step	▲ 7%
Total debts	€ 750,749 Total debts 2022: € 750,749 First fiscal year in the series	€ 634,426 Total debts 2023: € 634,426 ▼ 15% vs 2022 (€ 750,749) Favourable step	€ 627,233 Total debts 2024: € 627,233 ▼ 1% vs 2023 (€ 634,426) Favourable step	€ 556,672 Total debts 2025: € 556,672 ▼ 11% vs 2024 (€ 627,233) Favourable step	▼ 11%
Cash	€ 35,418 Cash 2022: € 35,418 First fiscal year in the series	€ 25,823 Cash 2023: € 25,823 ▼ 27% vs 2022 (€ 35,418) Unfavourable step	€ 36,906 Cash 2024: € 36,906 ▲ 43% vs 2023 (€ 25,823) Favourable step	€ 29,044 Cash 2025: € 29,044 ▼ 21% vs 2024 (€ 36,906) Unfavourable step	▼ 21%
Retained profit	€ 720,469 Retained profit 2022: € 720,469 First fiscal year in the series	€ 827,204 Retained profit 2023: € 827,204 ▲ 15% vs 2022 (€ 720,469) Favourable step	€ 895,489 Retained profit 2024: € 895,489 ▲ 8% vs 2023 (€ 827,204) Favourable step	€ 958,837 Retained profit 2025: € 958,837 ▲ 7% vs 2024 (€ 895,489) Favourable step	▲ 7%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 8,600 Dividend 2023: € 8,600 Unchanged (€ 0) Unchanged	€ 46,000 Dividend 2024: € 46,000 ▲ € 37,400 vs 2023 (€ 8,600) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 46,000) Unchanged	▼ 100%
Bank debt	€ 708,133 Bank debt 2022: € 708,133 First fiscal year in the series	€ 605,000 Bank debt 2023: € 605,000 ▼ 15% vs 2022 (€ 708,133) Favourable step	€ 573,151 Bank debt 2024: € 573,151 ▼ 5% vs 2023 (€ 605,000) Favourable step	€ 539,981 Bank debt 2025: € 539,981 ▼ 6% vs 2024 (€ 573,151) Favourable step	▼ 6%
Balance sheet total	€ 1,521,218 Balance sheet total 2022: € 1,521,218 First fiscal year in the series	€ 1,511,630 Balance sheet total 2023: € 1,511,630 ▼ 1% vs 2022 (€ 1,521,218) Unchanged	€ 1,572,722 Balance sheet total 2024: € 1,572,722 ▲ 4% vs 2023 (€ 1,511,630) Unchanged	€ 1,565,508 Balance sheet total 2025: € 1,565,508 Unchanged (€ 1,572,722) Unchanged

Key figures of Panacea Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to Panacea Pharma?

What happened at Panacea Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 28, 2025 New annual accounts for financial year 2025: profit of € 63,348 (▼ 45% vs 2024). Source: NBB ↗
Dec 10, 2012 New establishment in Putte. KBO
2012 Stefan Puttemans became a director. NBB
Dec 10, 2012 Start of the company according to the CBE. KBO

In short

From € 189,414 profit in 2022 to € 63,348 profit in 2025.

Paid € 86,892 in corporate taxes since 2022.

Best year ever: 2022, with € 189,414 profit.

Paid out € 54,600 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Stefan Puttemans

Panacea Pharma

Apotheek Puttemans-Vernaillen 94.9%

Behind Panacea Pharma is Stefan Puttemans. It owns 94.9% of Apotheek Puttemans-Vernaillen itself.

Directors

According to the 2025 annual accounts

Stefan Puttemans

Director

since 2012

Establishments

Establishment units

Physical locations of this company

Registered office

Lierbaan 37

2580 Putte

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

APOTHEEK PUTTEMANS-VERNAILLEN same network

€ 413,332 gross margin · 2025

Vereniging van mede-eigenaars Residentie De Farmacie

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0501.960.053

VAT number

BE 0501.960.053

Registered office

Lierbaan 37, 2580 Putte

Names & denominations

Panacea Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

10 December 2012

Peppol

Active · Active since 8 Dec 2025

Activities · NACE

Activiteiten van holdings

Holdings

Groothandel in farmaceutische en medische artikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Overige zakelijke dienstverlening, neg

Activiteiten van adviesbureaus op het gebied van public relations en communicatie

Handel in eigen onroerend goed

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

Panacea Pharma

Warning lights

Financials

What happened to Panacea Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions